Devices Treat Obesity Patients without Options

Early intervention is the general rule for success in treating many diseases, but in obesity, patients have to be in bad shape before they're eligible for the most efficacious treatments, which are surgical interventions. Companies with minimally invasive--and anatomy sparing--devices hope to change that paradigm.

Whether one eats to live or lives to eat, modern man’s relationship with food has clearly gotten out of control. In the US, more than two-thirds of adults age 20 and older are now classified as overweight or obese, to the tune of 127 million overweight adults, 66 million obese adults ,and 9 million morbidly obese adults, according to a report published in February by the Medtech Insight division of Windhover Information. (See, "US Marketsfor Obesity Drugs and Bariatric Surgical Devices".) The US is by no means the only country in which the combination of an increasingly sedentary lifestyle and a diet high in fats has created an obesity epidemic. The prevalence of obesity is increasing across the globe, from Europe to Southeast Asia. Today, more than 1.1 billion adults worldwide are overweight and 312 million of them are obese. What bodes even worse for the future: 155 million children worldwide are overweight or obese according to the World Health Organization.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By 

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By 

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.